Orthofix International NV (NASDAQ:OFIX) shares traded down 1.9% during mid-day trading on Friday . The company traded as low as $44.98 and last traded at $45.85, with a volume of 64,414 shares traded. The stock had previously closed at $46.75.

A number of research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Orthofix International NV from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 4th. TheStreet upgraded shares of Orthofix International NV from a “hold” rating to a “buy” rating in a research report on Monday, May 2nd.

The firm has a market cap of $840.04 million and a PE ratio of 91.25. The stock has a 50-day moving average price of $44.82 and a 200 day moving average price of $41.63.

Orthofix International NV (NASDAQ:OFIX) last released its quarterly earnings results on Thursday, April 28th. The medical device company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.13. The firm had revenue of $98.70 million for the quarter, compared to the consensus estimate of $93.10 million. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.15) earnings per share. Equities research analysts expect that Orthofix International NV will post $1.35 earnings per share for the current year.

In other Orthofix International NV news, Director Maria Sainz sold 4,157 shares of Orthofix International NV stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $46.33, for a total value of $192,593.81. Following the sale, the director now owns 20,828 shares of the company’s stock, valued at $964,961.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Michael Finegan sold 80,972 shares of Orthofix International NV stock in a transaction dated Monday, April 18th. The stock was sold at an average price of $42.71, for a total transaction of $3,458,314.12. Following the completion of the sale, the insider now directly owns 90,996 shares in the company, valued at approximately $3,886,439.16. The disclosure for this sale can be found here.

A number of hedge funds recently made changes to their positions in OFIX. Dimensional Fund Advisors LP raised its stake in shares of Orthofix International NV by 6.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 757,718 shares of the medical device company’s stock valued at $29,710,000 after buying an additional 46,204 shares in the last quarter. Diamond Hill Capital Management Inc. raised its stake in shares of Orthofix International NV by 5.6% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 861,860 shares of the medical device company’s stock valued at $33,794,000 after buying an additional 45,984 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Orthofix International NV during the fourth quarter valued at approximately $1,443,000. Russell Frank Co raised its stake in shares of Orthofix International NV by 80.3% in the fourth quarter. Russell Frank Co now owns 43,978 shares of the medical device company’s stock valued at $1,741,000 after buying an additional 19,582 shares in the last quarter. Finally, GSA Capital Partners LLP raised its stake in shares of Orthofix International NV by 18.3% in the fourth quarter. GSA Capital Partners LLP now owns 42,609 shares of the medical device company’s stock valued at $1,671,000 after buying an additional 6,601 shares in the last quarter.

Orthofix International N.V. (Orthofix) is a diversified, global medical device company focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians across the world. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.